The Experimental Irradiator Core maintains and operates sources of ionizing and non-ionizing radiation for use of Cancer Center members in their experimental studies. Studies performed by the resource staff include advice to users on design of experiments using radiation, training in operation of the sources, scheduling use of the resources, operating the resources when necessary, dosimetry for new experimental setups, and maintenance and repair of the resources. When not in use by members, these facilities and services are also available to non-members on an increased fee-basis. The primary resources of the facility are four Cs-137 irradiators that deliver ionizing radiation. Two Nordion Gammacell 40 irradiators are primarily used for whole-body irradiation of rodents and cell cultures at a constant dose rate. The Shepherd Mark I irradiator is primarily used to deliver radiation to animal tumors at doses compared to those used clinically in external beam radiotherapy or to sterilized cell cultures or other experimental samples. The low-dose-rate-irradiator, built-in-house, is used to deliver radiation to cell cultures and rodents in dose-rates similar to those used in tumor therapy using radioactive implants, and has been used in studies of carcinogenic processes by low- dose-rate radiation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006973-39
Application #
6474062
Study Section
Project Start
1978-01-01
Project End
2006-04-30
Budget Start
Budget End
Support Year
39
Fiscal Year
2001
Total Cost
$189,195
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Woodard, Lauren E; Dennis, Cindi L; Borchers, Julie A et al. (2018) Nanoparticle architecture preserves magnetic properties during coating to enable robust multi-modal functionality. Sci Rep 8:12706
Shrestha, Eva; White, James R; Yu, Shu-Han et al. (2018) Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol 199:161-171
Gordy, James T; Luo, Kun; Francica, Brian et al. (2018) Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3?-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons. J Immunother 41:181-189
El-Diwany, Ramy; Soliman, Mary; Sugawara, Sho et al. (2018) CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans. Sci Adv 4:eaat0843
Kyker-Snowman, Kelly; Erlanger Avigdor, Bracha; Nasim, Mansoor et al. (2018) A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing. Breast Cancer Res Treat 170:425-430
Christenson, Eric S; Antonarakis, Emmanuel S (2018) PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opin Emerg Drugs 23:123-133
Ambinder, Richard F (2018) A viral protein kinase drug target for tumors? J Clin Invest 128:2197-2198
Lee, Alice J; Montgomery, Madeline C; Patel, Rupa R et al. (2018) Improving Insurance and Health Care Systems to Ensure Better Access to Sexually Transmitted Disease Testing and Prevention. Sex Transm Dis 45:283-286
Bharathy, Narendra; Berlow, Noah E; Wang, Eric et al. (2018) The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma. Sci Signal 11:
McGrath-Morrow, Sharon A; Ndeh, Roland; Helmin, Kathryn A et al. (2018) DNA methylation regulates the neonatal CD4+ T-cell response to pneumonia in mice. J Biol Chem 293:11772-11783

Showing the most recent 10 out of 2393 publications